New lupus drug PIT565 enters human safety trials
NCT ID NCT06335979
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be closely monitored for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Beijing, 100191, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Budapest, H-1083, Hungary
-
Novartis Investigative Site
Szeged, 6725, Hungary
-
Novartis Investigative Site
Leiden, South Holland, 2333 CL, Netherlands
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Bern, 3010, Switzerland